Abbott ADD-Vantage approvals
Firm received FDA approval Sept. 10 to market generic cephalothin in 1 gram and 2 gram vials in its ADD-Vantage system. The Abbott generic approval came four days after initial ADD-Vantage approval for Keflin, Lilly's brand of cephalothin ("The Pink Sheet" Sept. 16, T&G-6).
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.